Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

AstraZeneca Amended Collaboration Agreement with Ironwood Pharma in China Mainland

astrazeneca
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclotide), a first-in-class new tr...

FDA Granted Fast Track Designation for Development of Farxiga

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, ...

Imfinzi Showed Improved OS in SCLC Treating

AstraZeneca’s Imfinzi (durvalumab) has become the first immunotherapy to show both significant survival benefit and improved, durable responses in extensive-stage small cell lung cancer (SCLC), after ...

Schrödinger Announced Collaboration with AZ to Deploy Advanced Computing Platform

astrazeneca
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts. Schrödinger’s computational platform combines p...

AZ Received Approval for Tagrisso in China

AstraZeneca has scored another approval for one of its new drugs in China, this time getting a green light for Tagrisso as a first-line treatment for adults with EGFR-positive non-small cell lung canc...

Russian Supreme Court Supported AstraZeneca in Legal Fight with Jodas Expoim

The disputes between manufacturers of original drugs and their Russian rivals may have a new twist in the local market, as the Russian Supreme Court has supported AstraZeneca in its legal fight with J...

AZ Announced Pozitive Results from Brilinta Trials

AstraZeneca announced detailed results from the positive Phase III THEMIS trial which showed Brilinta (ticagrelor) plus aspirin reduced the relative risk for the composite of cardiovascular (CV) death...

MHRA Cleared API in AZ’s Calquence for Export to EU in No-Deal Brexit

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has added the active pharmaceutical ingredient (API) in AstraZeneca’s Calquence to the list of materials cleared for export to the E...

AstraZeneca Announced Positive Results from Phase III ETHOS Trial of Breztri Aerosphere

AstraZeneca announced positive results from the Phase III ETHOS trialfor triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pul...

FDA Granted AZ’s Fasenra Orphan Drug Designation

fda
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis. EoE is a rare, chr...

China Becomes First Country to Approve Roxadustat for Chronic Kidney Disease Patients with Anaemia

china street
AstraZeneca announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anae...

AstraZeneca to Buy FDA Priority Review Voucher from Sobi for $95m

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitr...

AstraZeneca Announced Final Results from Global Trial of Imfinzi

astrazeneca
AstraZeneca announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimuma...

AstraZeneca Announced Positive Results from Phase III DAPA-HF Trial of Farxiga

astrazeneca
AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clini...

FDA Granted Breakthrough Therapy Designation for Calquence

astrazeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for adult patients with...

AstraZeneca Announced Positive Results from Phase III Trial of Tagrisso

astrazeneca
AstraZeneca announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patient...